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Abstract
Background: McH-lpr/lpr-RA1 mice are a new strain of mice which spontaneously develop destructive arthritis and
enthesitis in the ankle. There is no published data that drug treatment has been trialed on these mice. This study
examined the effect of the mouse anti-IL-6 receptor antibody, MR16–1, for the treatment of arthritis and enthesitis
in McH-lpr/lpr-RA1 mice.
Methods: Male McH-lpr/lpr-RA1 mice were randomly divided into control and treatment groups. MR16–1 was
administered from 10 weeks of age for the treatment group. Saline was applied for the control group. The drug
was administered once a week, at an initial dose of 2 mg, then maintained at 0.5 mg once per week thereafter. The
effects were evaluated by the histopathological synovitis score, in vivo imaging using indocyanine green liposomes,
and analysis of the gene expression of inflammatory cytokines.
Results: Tissue analyses were carried out at 14, 17 and 20 weeks of age. The synovitis scores of treated groups were
significantly lower compared with those of the control group at 14 and 17weeks of age. The kappa coefficient was 0.77.
However, progression of entheseal ossification persisted in the MR16–1 treated group. In vivo imaging using indocyanine
green liposomes showed significant decreases in signal intensities of treated groups at week 14, but no significant
differences were observed at week 18. Blood serum amyloid A levels in treated groups were significantly lower at 17
weeks of age. The gene expression levels of Tnf and Il17 were also significantly lower in MR16–1 treated groups.
Conclusions: Administration of the anti-IL-6 receptor antibody is effective for the treatment of synovitis and bone
destruction of McH-lpr/lpr-RA1 mice. McH-lpr/lpr-RA1 mice may be a suitable experimental model for the development
of new treatments for destructive arthritis and enthesitis. IL-6 signal blockade could contribute to the treatment of
destructive arthritis, and further studies should be carried out to confirm its potential in the prevention of enthesopathy
developed to ossification.
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Background
Autoimmune arthritis diseases with entheseal inflamma-
tion show complex pathological features, including syno-
vitis, bone erosion, enthesitis [1]. The imbalance of bone
and cartilage formation and the destruction of joint
structure results in the structural changes observed in
these diseases. Rheumatoid arthritis is characterized by
synovial proliferation and erosion of joint cartilage due
to chronic inflammation [2]. On the other hand, auto-
immune arthritis with entheseal inflammation like as
psoriatic arthrits involves a distinct remodeling process
leading to entheseal ossification with synovial prolifera-
tion and bone erosion [3, 4]. The histological character-
istics of entheseal ossification include the proliferation of
cartilage formation, and subsequent replacement of car-
tilage by bone (endochondral ossification) [5, 6]. Recent
studies have reported that IL-17 and IL-22 signaling
molecules released from IL-23 positive T cells are in-
volved in entheseal chondral proliferation and ossifica-
tion [7, 8]. Patients with ossifying enthesitis are typically
treated with tumor necrosis factor (TNF)-α inhibitors.
However, the prevention of entheseal ossification is rec-
ognized as being difficult especially in advanced stages
of the disease [9–11]. Moreover, animal models of syno-
vitis with concomitant entheseal ossification are yet to
be established. It is necessary to study animal models of
synovitis with intercurrent entheseal ossification to elu-
cidate the pathological mechanisms of the disease, and
develop new treatment methods.
Our research group have previously reported the de-
velopment of a murine model with spontaneous, pro-
gressive synovitis and enthesitis in ankle joints [12].
Backcross generation mice were prepared using a non-
arthritis strain of mice, C3H/HeJ-lpr/lpr (C3H/lpr),
MRL/lpr × (MRL/lpr × C3H/lpr) F1. Among these N2
mice, we observed development of arthritis of the ankle
joints, with macroscopic swelling. We then began to
intercross the N2 mice, by selection based on swelling of
the ankle joints. Finally, we established a novel recom-
binant strain of mice, designated McH-lpr/lpr-RA1,
which showed a high incidence of arthritis with entheso-
pathy. Analysis of the destructive arthritis and enthesitis
processes may elucidate the fundamental mechanisms of
peripheral inflammation in spondyloarthritis.
The anti-IL-6 receptor monoclonal antibody is available
for clinical use in patients with rheumatoid arthritis, and
has been shown to have therapeutic effects in the treat-
ment of severe rheumatoid arthritis [13]. The effect of
anti-IL-6 treatment in patients with ankylosing spondylitis
has also been reported — studies revealed that the anti-
IL-6 receptor antibody did not prevent the progression of
spinal changes associated with ankylosis [14]. Further-
more, the effect of treatment with anti-IL-6 receptor anti-
body on peripheral arthritis of spondyloarthritis has also
been reported, but the study reported mainly about insuf-
ficient effects on spinal disorder and its use in entheseal
inflammation and ossification with destructive arthritis re-
mains unclear [15]. MR16–1 is a rat anti-IL-6 receptor
monoclonal antibody, as previously described in the litera-
ture [16]. MR16–1 is used in many experimental disease
models to assess the effects of blocking IL-6 signaling [17–
23]. McH-lpr/lpr-RA1 mice may provide a suitable animal
model to assess the therapeutic effects of IL-6 signal block-
ade in entheseal inflammation and ossification, and the ad-
ministration of MR16–1 will determine the potential
treatment effects of IL-6 ligand and receptor blockade.
The purpose of the present study is to investigate the
effect of MR16–1 for the treatment of ankle joint arth-
ritis with enthesopathy, and the mechanism of entheseal
inflammatory change and ossification in the experimen-
tal murine model of McH-lpr/lpr-RA1 mice. We hypoth-
esized that IL-6 signal blockade would suppress the
progression of synovial proliferation and entheseal ossifi-
cation in McH-lpr/lpr-RA1 mice.
Methods
Animals
McH/lpr-RA1 mice were generated using F54 C3H/HeJ-
lpr/lpr and MRL/lpr × (MRL/lpr × C3H/lpr) mice in the
animal unit of Tohoku University Medical School. This
recombinant congenic strain of mice was designated
McH/lpr-RA1 as previously described in the literature
[12]. All mice were housed in the animal unit of Tohoku
University Medical School, an environmentally controlled
and specific pathogen-free facility. Animal protocols were
reviewed and approved by the Tohoku University Animal
Studies Committee. The animal experiments approval
number of our institute was 2015-MdA-247-1. The ani-
mals were maintained in individually-ventilated cage (225
× 338 × 140mm) at 22 ± 2 °C and 40 ± 20% humidity, re-
ceiving water and specific animal pellet-type laboratory-
animal food. All experiments were performed using week
10 male mice. The mice were randomly allocated to treat-
ment and control groups at week 10. The animals were
euthanized in a carbon dioxide gas chamber at 14–20
weeks of age.
Treatment of mice
IL-6 signal blockade was performed with an intraperito-
neal injection of 2 mg of rat anti-mouse IL-6R mAb
(MR16–1, a kind gift from Chugai Pharmaceutical, Tokyo,
Japan), once in the first treatment (week 10). Thereafter,
0.5 mg of MR 16–1 was administered once a week until
20 weeks of age as previously described in the literature
[24] Phosphate buffered saline (PBS) was administered on
the same schedule as a negative control.
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Enzyme-linked immunosorbent assay
Serum amyloid A (SAA) and IL-6 levels were determined
using an enzyme-linked immunosorbent assay (ELISA) kit
for SAA and IL-6 (Biosource, Camarillo, CA and R&D
Systems Inc., Minneapolis, MN, USA) according to the
manufacturer’s recommendations at 14 and 17 weeks of
age (n = 5 for each group). Briefly, serum samples were di-
luted 1:200 in assay diluent and incubated with conjugated
anti-mouse SAA antibody. Serum samples were incubated
with anti-mouse IL-6 antibody without dilution. Substrate
tetramethylbenzidine was added, samples were read at
OD450 nm and results were analyzed using the four-
parameter fit to determine SAA values.
Histomorphometric analysis
Ankle joints were harvested at 14, 17 and 20 weeks of
age and decalcified by soaking in 220 mM/L EDTA-Na
for 3 weeks. Decalcified samples were sectioned and
stained with hematoxylin and eosin for histopatho-
logical evaluation of synovitis and ankylosis, as
previously described in the literature [25]. The calcu-
lated synovitis score was the sum of scores for: enlarge-
ment of the synovial lining cell layer (0 points:
thickness of 1 layer; 1 point: thickness of 2–3 layers; 2
points: thickness of 4–5 layers; 3 points: thickness of
more than 5 layers), density of the resident cells (0
points: normal cellularity; 1 point: slightly increased
cellularity; 2 points: moderately increased cellularity; 3
points: greatly increased cellularity, pannus formation
and rheumatoid like granulomas might occur) and in-
flammatory infiltrate (0 points: no inflammatory infil-
trate; 1 point: few lymphocytes or plasma cells; 2
points: numerous lymphocytes or plasma cells, some-
times forming follicle-like aggregates; 3 points: dense,
band-like inflammatory infiltrate, or numerous large,
follicle-like aggregates). The values were summarized
and interpreted as follows, 0–1:no synovitis; 2–4: low
grade synovitis; 5–9: high grade synovitis. The synovitis
score was assessed by two researchers and the kappa
coefficient was calculated (n = 5 for each group).
Fig. 1 ELISA assays for SAA and IL-6. a ELISA assay for SAA at week 14 and 17. Serum SAA level is significantly lower in MR16–1 treated group at
week 17. b ELISA assay for IL-6 at week 14 and 17. There is no significant difference in serum IL-6 level. Results are expressed as the mean ±
standard error (n = 5 mice per group). Representative data are shown from three independent experiments with similar results. *p < 0.05 by two-
way ANOVA with Dunn’s multiple comparison test
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Synthesis of indocyanine green liposomes
Indocyanine green (ICG) liposomes were prepared as
previously described in the literature [26–28]. Briefly, 1,
2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC;
NOF, Tokyo, Japan) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy-(polyethylene gly-
col)-2000] (DSPE-PEG[2000-OMe]) (DSPE-PEG:NOF,
94:6 mol/mol) were placed in a pear-shaped flask, and
chloroform was added until the lipids were completely
dissolved. The chloroform was then evaporated under
reduced pressure using a rotary evaporator (NVC-2100/
N-1000, Eyela, Tokyo, Japan) until a lipid film remained.
Next, 100 μM of ICG (Daiichi Sankyo, Tokyo, Japan)
dissolved in 10mL PBS was added to the thin lipid film
to form multi-lamellar liposome vesicles. After repeated
freeze-thaw cycles, the size of the liposomes was ad-
justed to < 100 nm using extrusion equipment (Northern
Lipids Inc., Vancouver, BC, Canada) with four filter sizes
(100, 200, 400 and 600 nm; Nuclepore Track-Etch Mem-
brane, Whatman plc, Maidstone, UK). For sterilization, li-
posomes were passed through a 0.45 μm pore size filter
(Millex HV filter unit, Durapore polyvinylidene-difluoride
[PVDF] membrane, EMD Millipore, Billerica, MA, USA).
Unbound ICG was removed using PD-10 columns. The
lipid concentration was measured using the Wako Phos-
pholipids C test (Wako Pure Chemical Industries, Osaka,
Japan), and adjusted to 1.0 μmol/mL. Diameters of the
ICG liposomes were measured using a particle size
analyzer (ELSZ-2, Otsuka Electronics, Osaka, Japan).
In vivo bioluminescence imaging system analysis
Previous reports indicate that Near-infrared fluorescence
imaging system with ICG show significant accumulation
in inflamed joints with enhanced permeability and reten-
tion (EPR), like as the accumulation observed in tumors
Fig. 2 Histological images of control and MR16–1 treated groups at week 14. Representative histological images of ankle joint and foot in control
group. a is × 40 lower magnification image. b is × 100 higher magnification image. Rectangle shows the higher magnification area. Arrows
indicate synovial proliferation. * indicates entheseal fibrous and cartilaginous ankylosis. Representative histological images of ankle joint and foot
in MR16–1 treatment group. c is × 40 lower magnification image. d is × 100 higher magnification image. Rectangle shows the higher
magnification area. Arrows indicate synovial proliferation. * indicates fibrous and cartilaginous ankylosis
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[29, 30]. Blood vessel insufficiency of inflamed joints in
arthritic experimental models increases the leakiness and
permeability, which enhances the accumulation of lipo-
somes in arthritic lesion by EPR [31]. For the detection of
the arthritic inflammation and the proliferation of dys-
functional blood vessels, In vivo bioluminescence imaging
system (IVIS) analysis was performed at 10, 14 and 18
weeks of age in MR16–1 treated and control mice (n = 5
for each group). Two hundred μl of ICG liposomes was
administered intravenously. The fluorescence intensity of
leaked ICG was measured at 0, 5, 30, 60, 120 and 180min
after injection using an IVIS; Xenogen, Alameda, CA,
USA), as previously described in the literature [26, 27].
Quantitative RT-PCR
Synovial tissue specimens from ankle joints were har-
vested at 10, 14 and 16 weeks of age (n = 5 for each
group). Total RNA was extracted using QIAzol Lysis Re-
agent (Qiagen, Hilden, Germany) and an RNeasy Mini
Kit (Qiagen, Hilden, Germany). Synthesis of cDNA from
total RNA was carried out using RT buffer, RT random
primers, dNTP mix, and Multiscribe reverse transcript-
ase (Applied Biosystems, Foster city, CA, USA). A total
of 9 μL cDNA diluted 1:9 was added to 10 μL Taqman
Universal Master Mix II with Uracil N-glycosylase
(Applied Biosystems, Foster City, CA, USA). Real-time
amplification of the genes was performed using 1 μL ready-
to-use Taqman Gene Expression Assays (Applied Biosys-
tems) for Il6, Tnf, IL17, and gapdh as an endogenous
control (assay IDs: Mm00446190_m1, Mm00443260_g1,
Mm00439618_m1, and Mm99999915_g1). Relative gene
expression data were analyzed using the delta-delta-Ct
method with PCR-efficiency correction using StepOne
software version 2.2.2 (Applied Biosystems), as previously
described in the literature [32].
Fig. 3 Histological images of control and MR16–1 treated groups at week 17. Representative histological images of ankle joint and foot in control
group. a is × 40 lower magnification image. b is × 100 higher magnification image. Rectangle shows the higher magnification area. Arrows
indicate synovial proliferation. * indicates entheseal fibrous and cartilaginous ankylosis. Representative histological images of ankle joint and foot
in MR16–1 treatment group. c is × 40 lower magnification image. d is × 100 higher magnification image. Rectangle shows the higher
magnification area. Arrows indicate synovial proliferation. * indicates entheseal fibrous and cartilaginous ankylosis
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Microcomputed tomography analysis
Microcomputed tomography (micro-CT) imaging was
performed at 20 weeks of age (n = 5 for each group).
Harvested tibiae were stored in 70% ethanol at 4 °C,
and analyzed using a micro-CT scanner (Scan
Xmate-L090; Comscan Techno Co. Ltd., Kanagawa,
Japan) operated at a peak voltage of 75 kV and
100 μA. The scanned region included 505 images
from the proximal end of the tibia, at a resolution of
10.4 μm per voxel, and an image size of 516 × 506
pixels. Bone volume (BV; mm2), total volume (TV;
mm2), bone volume fraction (BV/TV; %) and tra-
becular thickness (mm) were evaluated and calcu-
lated from the axial slice of the proximal tibia using
TRI/3D-BON software (Ratoc System Engineering
Co., Tokyo, Japan), as previously described in the
literature [33].
Statistical analysis
Statistical analyses were performed using JMP software
version 13.1 (SAS, Cary, NC, USA). All data are expressed
as the mean ± standard error (SE). Statistical significance
of the differences between values were evaluated using the
Student’s t-test, two-way analysis of variance (ANOVA)
with Tukey’s multiple comparison test and two-way
ANOVA with Dunn’s multiple comparison test. Values of
p < 0.05 were regarded as statistically significant. Kappa




The results of the ELISA assays showed reduced levels of
SAA in the MR16–1 treatment group at 14 weeks of age,
with significantly decreased levels at week 17 (p = 0.04)
Fig. 4 Histological images of control and MR16–1 treated groups at week 20. Representative histological images of ankle joint and foot in control
group. a is × 40 lower magnification image. b is × 100 higher magnification image. Rectangle shows the higher magnification area. Arrow heads
indicate subsequent interosseous ankylosis after synovial proliferation. * indicates entheseal fibrous and cartilaginous ankylosis. Representative
histological images of ankle joint and foot in MR16–1 treatment group. c is × 40 lower magnification image. d is × 100 higher magnification
image. Rectangle shows the higher magnification area. * indicates entheseal fibrous and cartilaginous ankylosis
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(Fig. 1a). The results of the assay for serum IL-6 indicated
no significant difference between the control and MR16–1
treatment groups at 14 and 17weeks of age (Fig. 1b).
Histomorphometric analysis
At 14 weeks of age, control group mice showed appar-
ent synovitis, pannus formation, entheseal inflamma-
tion and ankylosis in the ankle region (Fig. 2a and b).
In MR16–1 treated mice, synovitis and pannus forma-
tion was suppressed compared with the control group
(Fig. 2c and d). At 17 weeks of age, control group mice
exhibited acceleration of synovitis, pannus formation
and ankle joint ankylosis (Fig. 3a and b). In the MR16–
1 treatment group, no synovitis or pannus formation
were detected, however, the progression of entheseal in-
flammatory cells filtration and ankylosis were seen (Fig.
3c and d). At 20 weeks of age, control group mice
showed degenerative synovial lesions, advanced pannus
formation and joint ankylosing change (Fig. 4a and b).
In the MR16–1 treatment group, inflammatory cells
Fig. 6 IVIS analyses in control and MR16–1 treated mice. a Representative image of IVIS of control mouse at week 14. There are evident signals in
both ankles and foots. b Representative image of IVIS of MR16–1 treated mouse at week 14. There are no significant uptake signals in ankles
and foots
Fig. 5 Histomorphometric analyses with the synovitis grading score of foot and ankle joints in control and MR16–1 treated mice. The synovitis
grading scores of MR16–1 treatment group are significantly lower in week 14, 17 and 20 compared with those of control group. Results are
expressed as the mean ± standard error (n = 5 mice per group). Representative data are shown from three independent experiments with similar
results. **p < 0.01, ***p < 0.001 by two-way ANOVA with Tukey’s multiple comparison test
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filtration and ankylosis of the entheseal area were
found, although synovitis and pannus formation were
absent (Fig. 4c and d). Histopathological assessments of
ankle arthritis were performed by calculation of the
synovitis score. The Kappa coefficient was calculated to
be 0.77, and the reproducibility was good. At week 14,
the synovitis score of the control group was 4.29 ± 019,
and that of the MR16–1 group was 2.75 ± 0.53. This in-
dicates a significant difference between the two groups
(p = 0.0098). At week 17, the synovitis score of the con-
trol group was 3.95 ± 0.22, and that of the MR16–1
group was 1.64 ± 0.27. This indicates a significant dif-
ference between the two groups (p < 0.001). At week 20,
the synovitis score of the control group was 3.33 ± 0.28,
and that of the MR16–1 group was 2.25 ± 0.3. This in-
dicates no significant difference between the groups
(Fig. 5). Even in the MR16–1 group, the synovitis score
was not completely suppressed due to the presence of
inflammatory cells filtration of entheseal area.
IVIS analysis
The changes in the signal intensities pre-injection and
120 min after injection were assessed. Representative im-
ages of 14 weeks of age control mice and MR16–1
treated mice are shown in Fig. 6a and b. MR16–1 treated
mice did not show ICG accumulation in the ankle or
foot joints. However, control mice showed obvious accu-
mulation in the foot and ankle joints. The results of IVIS
analyses are shown in Fig. 7. Quantitative IVIS was car-
ried out at weeks 10, 14 and 18 in control and MR16–1
treated mice. There was a significant difference in the
signal intensities of control and MR16–1 treated mice at
week 14 (p = 0.041), although there no significant differ-
ences were seen at weeks 10 or 18.
Quantitative RT-PCR
The results of quantitative PCR analyses are shown in
Fig. 8. Tnf gene expression gradually decreased until week
16 in the MR16–1 treatment group. There was a signifi-
cant difference in Tnf gene expression between the groups
at week 16 (p = 0.001), which was lower in the MR16–1
treated group than the control group. Il17 gene expression
also gradually decreased until week 16 in the MR16–1
treatment group. There was also a significant difference in
Il17 gene expression between the groups at week 16 (p =
0.022), which was lower in MR16–1 treated group. Il6
gene expression was also evaluated, revealing no signifi-
cant difference in expression levels between the groups.
Micro CT analysis
In the coronal-reconstructed micro CT images at 20
weeks of age, there were no apparent differences be-
tween MR16–1 treatment group and control group mice
(Fig. 9a). Quantitative structural analyses of proximal
tibia are shown in Fig. 9b. No significant differences
were seen in BV, TV, BV/TV or trabecular thickness be-
tween the two groups. MR16–1 treatment therefore does
not correlate with an increase in bone volume in McH/
lpr-RA1 mice.
Discussion
Previous studies have reported several murine models that
develop spontaneous ankylosis [34]. For example, DBA/1
mice spontaneously develop ankylosing arthropathy in the
ankle joints [35–37]. However, these mice mainly exhibit
fibrous proliferation in enthesis and fibrous ankylosis,
without erosion and bone destruction [34]. Furthermore,
other papers reported that the intraperitoneal injection of
β-1,3-glucan (curdlan) induced inflammatory arthritis and
Fig. 7 Quantitative analyses of signal intensity of IVIS at week 10, 14, 18. At week 14, the signal intensity of IVIS of ankles and foots is significantly
lower in MR16–1 treatment group, compared with the control group. There are no significant changes in week 10 and 18 in both groups. Results
are expressed as the mean ± standard error (n = 5 mice per group). Representative data are shown from three independent experiments with
similar results. * p < 0.05 by two-way ANOVA with Dunn’s multiple comparison test
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ankylosing spondylitis in SKG mice. These mice indicated
dactylitis, enthesitis, synovitis and destructive arthritis
[38–40]. SKG mice with the peritoneal injection of cur-
dlan show almost full symptoms of spondyloarthritis. Un-
like SKG mice, McH/lpr-RA1 mice spontaneously show
synovitis, pannus formation and entheseal ossification
without some specific pathogens [12]. We consider that
McH/lpr-RA1 mice are a suitable experimental disease
model of peripheral arthritis in spondyloarthritis. The
present study explores the effects of treatment with the
anti-IL-6 receptor monoclonal antibody in McH/lpr-RA1
mice. In the MR16–1 treated group, results of histomor-
phometric and IVIS analyses showed that the proliferation
of synovium and joint destruction were suppressed. How-
ever, histological investigations confirmed that entheseal
ossification and ankylosis progressed even with IL-6
blockade treatment. We propose that the anti-IL-6 recep-
tor antibody contributes to the suppression of synovial
proliferation and bone destruction in McH/lpr-RA1 mice,
but that further factors are involved in the prevention of
entheseal inflammation and ossification.
Changes in the bone parameters of MR16–1 treated
and control mice were evaluated by micro-CT imaging.
In this study there were no significant differences in the
bone parameters between two groups. Published studies
reported the treatment effects of MR16–1 to include in-
creased bone volume and bone strength in DBA/1 mice
with collagen-induced arthritis [22, 41]. However, in this
study McH/lpr-RA1 mice did not show increased bone
volume following MR16–1 treatment. In the published
study, the dose of MR16–1 was much higher — 8 mg
was administered to DBA/1 mice. Our different findings
of the effect of MR16–1 treatment on bone volume were
likely due to the different dosage of MR16–1.
SAA is related with the pathogenesis of rheumatoid
arthritis, and previous reports indicated that SAA was
linked to disease activity and treatment response of
rheumatoid arthritis [42, 43]. SAA is a suitable acute
Fig. 8 mRNA expression of Tnf, Il17 and Il6 genes. The expression levels of Tnf is significantly lower in MR16–1 treated group at week 16. The
expression levels of Il17 is significantly lower in MR16–1 treated group at week 16. There is no significant difference of Il6 expression among both
groups. Results are expressed as the mean ± standard error (n = 5 mice per group). Representative data are shown from three independent
experiments with similar results. *p < 0.05, ***p < 0.001 by two-way ANOVA with Tukey’s multiple comparison test
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phase reactant of mice [44, 45], and previous studies
showed that MR16–1 treatment suppressed the expres-
sion level serum SAA [21, 46]. SAA can be a relevant in-
flammation marker and useful for predicting the
treatment response in the arthritis and enthesitis in
McH/lpr-RA1 mice. SAA was significantly lower in the
MR16–1 treated group, and we consider that the dose of
MR16–1 that was administered is sufficient to suppress
inflammation in McH/lpr-RA1 mice. MR16–1 is an anti-
IL-6 receptor antibody for the treatment, so it is unsur-
prising that there were no changes in serum IL-6 level.
The results of quantitative RT-PCR showed that gene
expression levels of tnf and IL17 were suppressed by IL-
6 signal blockade. Previous studies reported that IL-6
signal blockade by MR16–1 suppresses IL-17 signaling
[47, 48]. Suppression of IL-6, TNF- ɑ and IL-17 signals
may contribute to the prevention of synovitis and bone
destruction in McH/lpr-RA1 mice. However, only partial
prevention of entheseal ossification and joint ankylosis
were seen in the MR16–1 treated group — at week 20
the histological images showed the progression of histo-
logical findings of entheseal ossification and ankylosis,
regardless of the prevention of synovial proliferation and
bone destruction. In the results of previous clinical trials,
administration of anti-IL-6 receptor antibody was insuf-
ficient for complete treatment of ankylosing spondylitis
[14]. Some studies have reported that entheseal ossifica-
tion in spondyloarthritis is related to IL-17 signaling
[49]. The blockade of IL-17 signaling was achieved in
this study; however, this signal suppression might be in-
sufficient, as other signaling pathways (such as IL-12, IL-
22 and IL-23) could be involved in the mechanisms of
entheseal ossification and ankylosis. Further studies
should be performed to assess the effects of IL-12, IL-22
and IL-23 signaling blockade for treatment of entheseal
ossification and ankylosis with McH/lpr-RA1 mice. We
consider that McH/lpr-RA1 is a useful animal model of
peripheral spondyloarthritis, and a promising tool for
the evaluation and development of new treatment re-
agents and drug repositioning treatment in destructive
arthritis and entheseal inflammation. SKG mice with the
peritoneal injection of curdlan seem to be a suitable ani-
mal model of spondyloarthritis, nevertheless the evalu-
ation and development of new treatment reagents
should be assessed in different strains of mice models,
including McH/lpr-RA1 mice.
Fig. 9 Micro CT image of tibia at week 20 in control and MR16–1 treated groups. a Representative coronal reconstruction images of proximal
tibia in control and MR16–1 treated groups. b Structural parameter analyses of tibia of control and MR16–1 treated mice. Results are expressed as
the mean ± standard error (n = 5 mice per group). Representative data are shown from two independent experiments with similar results. There
are no significant differences in BV, TV, BV/TV and trabecular thickness by Student’s t-test
Izumiyama et al. BMC Musculoskeletal Disorders          (2019) 20:286 Page 10 of 12
The results of IVIS analyses showed that there was a
significant difference between the two groups in week 14
only. These results are inconsistent with the results of
histological analyses, PCR and ELISA of SAA, which in-
dicated significant differences after week 14. We con-
sider that the proliferation of dysfunctional blood vessels
in inflamed joints of McH/lpr-RA1 mice decreases
around week 18. The histological findings showed sig-
nificant differences and advanced deformity in late phase
arthritis, including bone erosion, pannus formation and
ankylosis. The advancement of destructive arthritis and
ankylosis after the decreased formation of dysfunctional
blood vessels may induce the inconsistent results of IVIS
and histological synovitis score.
Conclusion
In the present study, we have demonstrated for the first
time that IL-6 signal blockade with MR16–1 significantly
reduces the development of synovitis and joint destruc-
tion in the murine experimental model of spontaneous
arthritis and enthesitis, McH/lpr-RA1. Our results indi-
cate that the progression of deformity associated with
entheseal ossification continue even with anti-IL-6 re-
ceptor antibody treatment; indicating that further factors
might be involved in the progression of entheseal ossifi-
cation. McH/lpr-RA1 is a promising animal model for
the elucidation of the mechanism of destructive arthritis
and enthesitis, and development of new treatment.
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